Equities

Guizhou Yibai Pharmaceutical Co Ltd

600594:SHH

Guizhou Yibai Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)3.09
  • Today's Change-0.04 / -1.28%
  • Shares traded7.66m
  • 1 Year change-45.21%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments696585380
Total Receivables, Net746808770
Total Inventory587625555
Prepaid expenses371516
Other current assets, total3.797.00--
Total current assets2,0692,0411,720
Property, plant & equipment, net1,7871,8571,756
Goodwill, net164164778
Intangibles, net331362379
Long term investments373738
Note receivable - long term------
Other long term assets------
Total assets4,5974,8665,068
LIABILITIES
Accounts payable135149141
Accrued expenses7511192
Notes payable/short-term debt446537454
Current portion long-term debt/capital leases128168120
Other current liabilities, total146208272
Total current liabilities9301,1731,079
Total long term debt425372328
Total debt9991,077903
Deferred income tax373030
Minority interest13414659
Other liabilities, total18710168
Total liabilities1,7131,8221,565
SHAREHOLDERS EQUITY
Common stock792792792
Additional paid-in capital654734766
Retained earnings (accumulated deficit)1,4381,5171,944
Treasury stock - common------
Unrealized gain (loss)0.650.991.19
Other equity, total------
Total equity2,8843,0443,503
Total liabilities & shareholders' equity4,5974,8665,068
Total common shares outstanding792792792
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.